

Lenvima Approval Status Worldwide (Country/ Region)

July, 2021

Thyroid cancer

Argentina	May-2019	Finland	May-2015	Luxembourg	May-2015	Singapore	Apr-2016
Australia	Jan-2016	France	May-2015	Macau	Sep-2015	Slovakia	May-2015
Austria	May-2015	Germany	May-2015	Malaysia	Nov-2016	Slovenia	May-2015
Bahrain	Dec-2019	Greece	May-2015	Malta	May-2015	South Africa	May-2020
Belgium	May-2015	Guatemala	Dec-2020	Mexico	May-2016	South Korea	Oct-2015
Brazil	Aug-2016	Hong Kong	May-2016	Morocco	Feb-2021	Spain	May-2015
Brunei	Dec-2018	Hungary	May-2015	Myanmar	Nov-2018	Sri Lanka	Feb-2019
Bulgaria	May-2015	Iceland	May-2015	Netherlands	May-2015	Sweden	May-2015
Cambodia	Apr-2019	India	Jan-2017	New Zealand	Apr-2020	Switzerland	Aug-2015
Canada	Dec-2015	Indonesia	Jul-2018	Norway	May-2015	Taiwan	Sep-2016
Chile	Jul-2019	Ireland	May-2015	Oman	Jan-2021	Thailand	Mar-2016
China	Nov-2020	Israel	Jan-2016	Pakistan	Dec-2020	UAE	Feb-2017
Costa Rica	Apr-2021	Italy	May-2015	Panama	Mar-2020	UK	May-2015
Croatia	May-2015	Japan	Mar-2015	Peru	May-2019	US	Feb-2015
Cyprus	May-2015	Jordan	Nov-2019	Philippines	Dec-2016	Vietnam	Jun-2020
Czech Republic	May-2015	Kuwait	May-2016	Poland	May-2015		
Denmark	May-2015	Latvia	May-2015	Portugal	May-2015		
Ecuador	Jul-2020	Lebanon	Nov-2016	Romania	May-2015		
Egypt	Mar-2021	Liechtenstein	May-2015	Russia	Dec-2015		
Estonia	May-2015	Lithuania	May-2015	Saudi Arabia	Dec-2019		

Note: The purpose of this document is to indicate that Eisai seeks to expand access to its products to patients in the world. Specific indication may vary in each country/region. Approval does not guarantee product availability.

Lenvima Approval Status Worldwide (Country/ Region)

July, 2021

2nd line Renal cell carcinoma

Argentina	May-2019	Guatemala	Dec-2020	Norway	Aug-2016	US	May-2016
Australia	Jul-2017	Hong Kong	Nov-2017	Pakistan	Dec-2020		
Austria	Aug-2016	Hungary	Aug-2016	Panama	Mar-2020		
Belgium	Aug-2016	Iceland	Aug-2016	Peru	May-2019		
Brazil	Oct-2018	India	Dec-2019	Philippines	Dec-2016		
Brunei	Dec-2018	Ireland	Aug-2016	Poland	Aug-2016		
Bulgaria	Aug-2016	Israel	Dec-2016	Portugal	Aug-2016		
Canada	Sep-2017	Italy	Aug-2016	Romania	Aug-2016		
Chile	Jul-2019	Latvia	Aug-2016	Russia	Sep-2016		
Costa Rica	Apr-2021	Lebanon	May-2017	Singapore	May-2017		
Croatia	Aug-2016	Liechtenstein	Aug-2016	Slovakia	Aug-2016		
Cyprus	Aug-2016	Lithuania	Aug-2016	Slovenia	Aug-2016		
Czech Republic	Aug-2016	Luxembourg	Aug-2016	South Africa	May-2020		
Denmark	Aug-2016	Macau	Jul-2018	Spain	Aug-2016		
Ecuador	Jul-2020	Malaysia	Oct-2018	Sri Lanka	Feb-2019		
Estonia	Aug-2016	Malta	Aug-2016	Sweden	Aug-2016		
Finland	Aug-2016	Mexico	Jan-2018	Switzerland	Aug-2017		
France	Aug-2016	Myanmar	Jun-2019	Taiwan	Jul-2017		
Germany	Aug-2016	Netherlands	Aug-2016	Thailand	Mar-2018		
Greece	Aug-2016	New Zealand	Apr-2020	UK	Aug-2016		

In Europe, lenvatinib is approved under the brand name Kispplx[®] for treatment of renal cell carcinoma

Note: The purpose of this document is to indicate that Eisai seeks to expand access to its products to patients in the world. Specific indication may vary in each country/region. Approval does not guarantee product availability.

Lenvima Approval Status Worldwide (Country/ Region)

July, 2021

Hepatocellular carcinoma

Argentina	May-2019	France	Aug-2018	Macau	Apr-2019	Slovenia	Aug-2018
Australia	Sep-2018	Germany	Aug-2018	Malaysia	Nov-2019	South Africa	May-2020
Austria	Aug-2018	Greece	Aug-2018	Malta	Aug-2018	South Korea	Aug-2018
Bahrain	May-2020	Guatemala	Dec-2020	Mexico	Apr-2020	Spain	Aug-2018
Belgium	Aug-2018	Hong Kong	Feb-2019	Morocco	Feb-2021	Sri Lanka	Feb-2019
Brazil	Feb-2019	Hungary	Aug-2018	Myanmar	Oct-2019	Sweden	Aug-2018
Brunei	Aug-2020	Iceland	Aug-2018	Netherlands	Aug-2018	Switzerland	Oct-2018
Bulgaria	Aug-2018	India	Mar-2019	New Zealand	Apr-2020	Taiwan	Nov-2018
Canada	Dec-2018	Indonesia	Nov-2019	Norway	Aug-2018	Thailand	May-2019
China	Sep-2018	Ireland	Aug-2018	Oman	Jan-2021	UAE	Jun-2019
Chile	Jul-2019	Israel	Apr-2019	Panama	Mar-2020	UK	Aug-2018
Costa Rica	Apr-2021	Italy	Aug-2018	Peru	May-2019	US	Aug-2018
Croatia	Aug-2018	Japan	Mar-2018	Philippines	Oct-2018	Vietnam	Jun-2020
Cyprus	Aug-2018	Jordan	Apr-2020	Poland	Aug-2018		
Czech Republic	Aug-2018	Kuwait	Nov-2020	Portugal	Aug-2018		
Denmark	Aug-2018	Latvia	Aug-2018	Romania	Aug-2018		
Ecuador	Jul-2020	Lebanon	Feb-2019	Russia	Oct-2018		
Egypt	Mar-2021	Liechtenstein	Aug-2018	Saudi Arabia	May-2020		
Estonia	Aug-2018	Lithuania	Aug-2018	Singapore	May-2019		
Finland	Aug-2018	Luxembourg	Aug-2018	Slovakia	Aug-2018		

Note: The purpose of this document is to indicate that Eisai seeks to expand access to its products to patients in the world. Specific indication may vary in each country/region. Approval does not guarantee product availability.

Lenvima Approval Status Worldwide (Country/ Region)

July, 2021

2nd line Endometrial Carcinoma(EC)

Australia	Sep-2019
Canada	Sep-2019
Hong Kong	Nov-2020
Macau	May-2021
Malaysia	Jul-2020
Philippines	Feb-2020
Russia	Jun-2020
Singapore	Oct-2020
South Korea	May-2020
Taiwan	Jun-2020
Thailand	Dec-2020
US	Sep-2019

Note: The purpose of this document is to indicate that Eisai seeks to expand access to its products to patients in the world. Specific indication may vary in each country/region. Approval does not guarantee product availability.